This book investigates the role of low-molecular-weight heparins (LMWHs) in preventing and treating thromboembolic diseases. It draws upon the expertise of H. Bounameaux to explore the pharmacological properties and clinical applications of these crucial anticoagulants. The text likely details the mechanisms by which LMWHs exert their effects, contrasting them with unfractionated heparin, and presents evidence from clinical trials and observational studies to support their use in various patient populations. The objective is to provide a comprehensive overview of LMWH therapy in managing conditions such as deep vein thrombosis and pulmonary embolism.

This work is positioned as a specialized medical text, likely aimed at clinicians and researchers in the fields of cardiology and hematology. Its focus on a specific class of anticoagulants suggests a deep dive into their pharmacokinetics, pharmacodynamics, and clinical efficacy. The author's presumed expertise in the area indicates a rigorous examination of the available scientific literature and clinical evidence. The book is expected to serve as a valuable reference for understanding the established and evolving role of LMWHs in managing thromboembolic disorders.